Literature DB >> 17939940

Scleromyxedema.

Warren R Heymann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17939940     DOI： 10.1016/j.jaad.2007.04.033

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  6 in total

1.  Scleromyxedema, a therapeutic dilemma.

Authors:  Julio Cesar Salas-Alanis; Brayant Martinez-Jaramillo; Minerva Gomez-Flores; Jorge Ocampo-Candiani
Journal:  Indian J Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.494

2.  Scleromyxedema: clinical diagnosis and autopsy findings.

Authors:  Ana Carolina Bulhões Sala; Paulo Rowilson Cunha; Clóvis Antônio Lopes Pinto; Célia Antônia Xavier de Moraes Alves; Ingrid Barreto Paiva; Ana Paula Vieira Araujo
Journal:  An Bras Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.896

3.  Early onset of scleromyxedema Arndt-Gottron associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.

Authors:  Asma Kefi; Fatima Jaziri; Khaoula Ben Abdelghani; Sami Turki
Journal:  Clin Case Rep       Date:  2022-08-03

4.  Arndt Gottron scleromyxedema: successful response to treatment with steroid minipulse and methotrexate.

Authors:  Vandana Mehta; C Balachandran; Raghavendra Rao
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

5.  Scleromyxedema: a case report and review of the literature.

Authors:  Mohamed Allam; Mohamed Ghozzi
Journal:  Case Rep Dermatol       Date:  2013-06-11

6.  Long-term efficacy of high doses of intravenous immunoglobulins in generalized scleromyxoedema: Case report.

Authors:  Federica Arginelli; Franco Rongioletti; Giampiero Girolomoni; Giovanni Pellacani; Davide Guardoli; Andrea Conti
Journal:  J Int Med Res       Date:  2016-09       Impact factor: 1.671
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.